By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pharmacogenomic test development firm Foundation Medicine today announced a collaboration with Novartis to develop, enhance, and optimize Foundation's cancer genome panel test.

The deal is Foundation's first with a drug firm, and if the pilot phase is successful the two companies will evaluate opportunities to commercialize the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.